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Introduction 
 
According to the definition of WHO epilepsy is a chronic 
neurological disorder with various etiologies that affects people of 
all ages and is characterized by recurrent seizures. Approximately 5 
million people worldwide have epilepsy. Seizures can vary from the 
briefest lapses of attention or muscle jerks, to severe and prolonged 
convulsions (i.e. violent and involuntary contractions, or a series of 
contractions, of the muscles). Seizures can also vary in occurrence, 
from less than one per year to several times per day.  
At the neuronal network level it manifests as a state of 
pathological hyperexcitability and hypersynchronous activity. 
Imbalanced synaptic inputs may cause excessive neuronal activity, 
eventually leading to neuronal death and synaptic reorganization.  
Though, nowadays a high variety of antiepileptic drugs are available, 
a significant number of patients are pharmacoresistant (cannot be 
cured with medication). In case of therapy resistant patients with 
severe clinical consequences, and where the epileptic focus can be 
precisely localized, epilepsy surgery is a possible solution. The aim 
of the surgery is ending seizures by lesioning the epileptogenic focus. 
Approximately 85% of partial epilepsies originate from the temporal 
lobe, thus the surgery most often carried out is anterior temporal 
lobectomy. 
 
The endocannabinoid system 
Activation of the endocannabinoid system is involved in 
numerous physiological functions like food intake, pain sensation 
and memory formation. In the brain, the endocannabinoid system is 
responsible for retrograde synaptic signaling via activation of 
cannabinoid receptors type 1 (CB1-Rs). Endocannabinoids are 
released from the postsynaptic neurons in an activity-dependent 
manner, and bind to presynaptically located CB1-Rs, thereby 
suppressing transmitter release from axon terminals. 
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In addition to its physiological roles, this system was found to 
be affected in pathological processes as well. Controversial data 
were published regarding the effects of cannabinoids in epilepsy. On 
one hand, in an animal model of temporal lobe epilepsy (TLE), 
CB1-R agonists displayed anti-epileptic effects, which were 
proposed to be mediated via attenuating glutamate release. On the 
other hand, proconvulsive effects of CB1-R agonists were described 
as well. Moreover, a CB1-R antagonist was shown to prevent the 
long-term increase in seizure susceptibility, when applied in a 
certain time-window.  
Moreover, human studies showed that recurrent seizures may 
lead to an adverse reorganization of the endocannabinoid system and 
to the impairment of its protective effect. CB1-Rs located at 
inhibitory synapses can be upregulated in the dentate gyrus, whereas 
downregulation of CB1-Rs located at excitatory synapses may occur 
in the inner molecular layer of the dentate stratum moleculare.  
 
Aims 
 
Specific questions we wished to answer: 
 
-How does the strength of acute seizures correlate with later cell 
death and reorganization? 
 
-What kind of anatomical changes can be found in the 
endocannabinoid system in the acute, the latent and the chronic 
phases of epilepsy at the light and electron microscopic levels? 
 
-What kind of changes can be seen in the function of the 
endocannabinoid system in the acute phase using in vitro slice 
preparations? 
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-Does the seizure susceptibility in CB1-R knock-out animals differ 
from controls? 
 
-Is the target distribution of CB1-R immunopositive elements altered 
in the mouse model of epilepsy and in human TLE patients?
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Materials and methods 
The pilocarpine model of epilepsy 
For this animal model 20-30 g male CD1 mice and CB1-R 
knock-out mice were used. Animals were assigned to control and 
experimental groups. Age-matched control mice were injected with 
physiological saline. Experimental mice were injected with 
intraperitoneal Pilocarpine hydrochloride (340 mg/kg) to induce 
status epilepticus (SE) Scopolamine methyl nitrate (5 mg/kg) was 
injected 30 minutes in advance to reduce peripheral cholinergic 
effects of pilocarpine. After injection the behavioral signs of 
seizures were monitored and scored. Seizures were classified by 
using the modified Racine’s scale (1-5), animals were separated into 
“weak” and “strong” groups according to their seizure activity. 
Seizure activity was defined for every animal by using the maximal 
value of Racine -scale reached more than once. 
Acute phase was examined 2 hours after pilocarpine injection. 
The period examined 1-3 days after the injection was regarded as the 
latent phase. EEG recordings were carried out 1 month after 
pilocarpine treatment in the chronic phase At this time point 
recurrent seizures occurred in most of the strong epileptic animals. 
 
In vivo electrophysiology 
Mice were anesthetized with a 1-1.5 % halothane-air mixture 
and secured in a stereotaxic frame. Stainless steel wire electrodes 
were placed on the skull and covered with conductive paste to 
decrease the impedance. The electrodes and the connector were 
embedded in dental acrylic cement. EEG activity was filtered at 1 
Hz to 70 Hz and amplified (20 k). Sampling rate was 500 Hz , 
amplification 20 µV/mm, filter: LP: 70Hz, HP: 1Hz.  
All EEG recordings were evaluated by three independent and 
experienced researchers to determine the occurrence of seizures or 
interictal spikes. EEG recordings were conducted out in 16 mice (6 
controls, 4 weak and 6 strong epileptic) in the chronic phase. In 4 
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animals (2 controls, 2 chronically epileptic ones) 24-hours EEG 
monitoring was carried out. 
 
Human tissue 
Hippocampal samples were obtained from patients (n=44) with 
therapy-resistant temporal lobe epilepsy. Patients with intractable 
temporal lobe epilepsy underwent standard anterior temporal 
lobectomy; the anterior third of the temporal lobe was removed 
together with the temporomedial structures. 
Control brain tissue (N=4) was obtained from 53-65 years old 
subjects with 2-4 hours post mortem delays. None of the control 
subjects had any record of neurological disorders. Brains were 
removed, the dissection was performed at the Forensic Pathology 
Department of the Semmelweis University Medical School. After 
surgical removal, the epileptic tissue was immediately dissected to 
3-4 mm thick blocks, and immersed into a fixative. 
 
Immunocytochemistry 
Brains were removed from the skull and 60 µm thick 
vibrotome sections were cut from the blocks. Following washing in 
PB, sections were cryoprotected in 30% sucrose for 1–2 days, and 
three times frozen over liquid nitrogen. Sections were processed for 
immunostaining against CB1-R, Neuronal Specific Nuclear Protein 
(NeuN) and Heat Shock protein 72 (HSP72) as follows. After H2O2 
treatment non-specific immunostaining was blocked and sections 
were incubated in the antibody for 2 days. For visualization 
biotinylated secondary antiserum was used followed by ABC. The 
immunoperoxidase reaction was developed by DAB as a chromogen. 
The control sections were processed in the same way.  
Ultrathin serial sections were collected on Formvar-coated 
single slot grids, stained with lead citrate, and examined with an 
electron microscope. 
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Gallyas silver impregnation 
The steps of this staining are the following: 2x5min in 2% 
NaOH and 2.5% NH4OH), 10 min in 0–0.8% NaOH, 2.5% NH4OH, 
0.5% AgNO3, 3x5 min in 0.5% Na2CO3 and 0.01% NH4NO3 in 30% 
ethanol, 1 min in 0.4–0.6% formaldehyde and 0.01% citric acid in 
10% ethanol, pH 5.0 –5.5, 3x10 min wash in 0.5% acetic acid.  
 
Nissl staining 
2 mins in xylene, 3 mins in ethanol abs., 3 mins in 90% 
ethanol, 3 mins in 70% ethanol, 3 mins in 50% ethanol, 5 mins in 
cresyle violet, rinse in 70% ethanol, rinse in 70% ethanol+drops of 
acetic acid for fixation, rinse in 90% ethanol, 3 mins in ethanol abs., 
2x3 mins of xylene. 
 
Quantitative electron microscopic analysis 
Ratio and number of symmetric and asymmetric synapses 
The quantity of symmetric and asymmetric synapses 
established by CB1-R-immunopositive axon terminals was 
examined in the stratum moleculare of 3 control, 3 chronic epileptic 
and 3 acute epileptic hippocampi. Serial sections were made from 
the blocks reembedded from stratum moleculare and examined using 
an electron microscope. CB1-R stained terminals were analyzed in 
every 10th section in order, following the rules of systematic random 
sampling. Significance was tested using Mann-Whitney U-test 
(Statistica 6.0). 
 
Target distribution of CB1-R immunopositive terminals 
Target distribution of CB1-R-immunopositive elements was 
studied in the stratum moleculare of the dentate gyrus in control and 
sclerotic subjects, where the highest fiber density was observed. 
Both in controls (N=105, two subjects) and in epileptic patients 
(N=175, 3 subjects) the postsynaptic target of CB1-R-
immunopositive terminals establishing symmetric synapses were 
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examined (photographed and quantified) at the electron microscopic 
level. 
 
 
Results 
 
Reorganization of CB1-R expressing GABAergic axons in 
temporal lobe epileptic patients 
 The expression pattern of CB1-Rs present at inhibitory 
synapses was studied by immunocytochemistry in epileptic 
hippocampal tissue derived from intractable TLE patients (N=44). 
The antibody used in this part of the study stained CB1-R-containing 
axon endings forming symmetric synapses with their postsynaptic 
targets. 
 In the hippocampi of human TLE patients the pattern of cell 
loss was analyzed by light microscope in sections immunostained 
for different neurochemical markers labeling principal and non-
principal cells. Based on anatomical alteration observed in the 
hippocampus patients could be classified into three different groups. 
(i) Epileptic Type 1 (mild) (n = 6): similar to control, no 
considerable cell loss is present in the pyramidal cell layer in the 
CA1 region , layers are visible and intact.  
(ii) Epileptic Type 2 (patchy) (n = 16): pyramidal cell loss is in 
patches in the CA1 pyramidal cell layer, but these parts are not 
atrophic. Interneuron loss is more pronounced.  
(iii) Epileptic Type 3 (sclerotic) (n = 22): the CA1 region is 
shrunken, and atrophic, more than 90% of principal cells are missing 
and occasionally scattered pyramidal cells remain in the CA1 region.  
In the present study the distribution and localization of CB1-R-
immunoreactive elements was studied in controls, in non-sclerotic 
(Type 1 and Type 2) and sclerotic cases (Type 3) 
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Distribution of CB1-R expressing GABAergic fibers in control 
and epileptic human hippocampus 
Immunostaining revealed numerous CB1-R-positive cell 
bodies of interneurons scattered in all hippocampal subfields. 
Dendrites remained unstained, but a dense meshwork of CB1-
R.immunoreactive axons covered the entire hippocampal formation. 
The strongest axonal labeling was found in stratum moleculare of 
the dentate gyrus, mostly in their inner part. Strong staining 
appeared also in stratum pyramidale of CA1-CA3 containing 
numerous axon terminals. In contrast, no apparent labeling occurred 
in the neuropil in the hilus and str. lucidum. 
In the non-sclerotic cases, the distribution of CB1-Rs in the dentate 
gyrus did not show any major changes compared to the normal post 
mortem controls. In contrast, a strong increase in CB1-R 
immunostaining was found in the dentate gyrus of epileptic patients 
with CA1 sclerosis, similar to what we have seen in the mouse 
model (see below). Immunopositive interneuron somata were 
preserved both in the dentate gyrus and in the CA1 area. The density 
of immunostained fibers increased in the dentate molecular layer 
and became inhomogeneous in the hilus forming dense arrays of 
boutons around the surviving mossy cells and interneurons.  
Qualitative analysis revealed an increased density of 
immunostained axonal meshworks in the sclerotic stratum 
moleculare compared to the control or non-sclerotic cases. To 
quantify this increase, sections with fluorescent immunostaining 
were processed in 3 control and 10 sclerotic cases, and the density of 
immunolabeling was measured by confocal laser scanning 
microscopy. The results showed that the density of fibers had 
significantly increased in epileptic cases (type 3). 
 
Ultrastructural analysis 
Electron microscopic examination confirmed that the antibody used 
in this study visualized CB1-Rs only on terminals giving symmetric 
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synapses. The cellular and subcellular localization of CB1-Rs was 
similar in the epileptic and control cases. Target distribution of CB1-
R-immunopositive elements was studied in the stratum moleculare 
of the dentate gyrus in control and sclerotic TLE subjects. 
Examination of immunogold terminals showed that CB1-Rs were 
localized in the membrane, outside the synaptic active zone. Both in 
controls (N=105, two subjects) and in epileptic patients (N=175, 
three subjects) the CB1-R-immunopositive terminals established 
symmetric synapses mostly on dendrites (75 v.72,5 %, spines 13,2 v. 
15,5 %, and cell bodies 11,8 v. 13 %, in control and epileptic 
subjects, respectively). 
 
Since changes affecting the endocannabinoid system described in 
the literature are quite confusing we used an animal model of TLE to 
study alterations of CB1-Rs in the acute, latent and chronic phases 
of epilepsy. 
 
Changes of CB1-R immunostained fibers in the mouse model of 
TLE 
 Epilepsy related alterations found in the human tissue were 
confirmed by examining changes in the same features in the mouse 
model (which shall be described in details later in the study). 
The upregulation of CB1-Rs linked to symmetric synapses was seen 
in the mouse model as well, similar to that in human patients.   
Quantification of the target distribution of CB1-R-immunopositive 
elements was carried out in the mouse model to compare it to those 
obtained from human tissues. Stratum moleculare of the dentate 
gyrus was studied in control and sclerotic animals. Similar to 
controls and human tissue, CB1-Rs were localized in the membrane, 
outside the synaptic active zone. Both in controls (N=53) and 
sclerotic cases (N=48) the target distribution of CB1-R 
immunopositive fibers was examined. Stained terminals established 
symmetric synapses mostly on dendrites (77.4 v.77.1%, spines 22.6 
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v.20.8% and cell bodies 0 v. 2.1 %). Thus, target distribution was 
unchanged, similar to results observed in human tissue. 
 
The pattern of cell loss in pilocarpine induced epilepsy  
In the next part we examined our animal model in more details. 
Based on the behavioral signs during the acute seizures, animals 
were classified as “weak” or “strong” epileptic animals using the 
modified Racine scale. Mice showing seizure intensity from Racine 
1 to Racine 4 (shaking, chewing, nodding, forelimb clonus, rearing 
but no tonic-clonic seizures) were assigned to the weak group. 
However, all animals in the strong group exhibited strong tonic-
clonic seizures (Racine 5) with other less severe behavioral 
manifestations. We examined the cell loss pattern in the hippocampi 
at different survival times using NeuN-immunostaining, GluR2/3-
immunostaining and Nissl staining.  
In the acute phase (2 hours) no cell loss was observed neither in the 
weak nor in the strong animals. In the latent phase (1-3 days post-
pilocarpine) loss of sensitive interneurons and few principal cells 
could be seen in the CA1 and CA3 regions.  In the chronic phase 
patchy cell loss was found infrequently in “weak” animals, but none 
of their hippocampi showed sclerosis. In contrast, hippocampi of the 
“strong” mice showed sclerosis in most cases (70%) meaning that 
CA1 and CA3 regions were shrunken, atrophic with more than the 
half of the cells missing. 
Based on the severity of cell death, the degree of damage affecting 
different subregions (CA1, CA3, DG) the following classification 
was used (with a semiquantitative scale):  type 1 (mild cell 
loss<10%), type 2 (patchy cell loss between 11-50%) and type 3 
(sclerotic, (cell loss over 50%,). Statistical analysis revealed a 
significant correlation between the degree of cell  loss and seizure 
strength in Racine scale values (105 animals; p<0.05; Pearson 
correlation). Thus, behavioral signs of the acute seizures could be 
used to predict the degree of cell loss in the chronic phase.  
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In vivo electrophysiological recordings 
EEG recordings were carried out in 16 mice (6 controls, 4 weakly 
and 6 strongly epileptic mice) in the chronic phase. On the basis of 
these recordings, the EEG activity of pilocarpine treated mice 
differed from controls. strong synchronization and numerous 
interictal spikes were seen separately or in clusters. In weak animals 
recurrent seizures were rarely seen (in 1 mouse out of 4), while 
interictal spikes (incidence 2.2±2.26Hz, amplitude 581±160 µV) 
occurred in all cases. In members of the strong group recurrent 
seizures appeared (ictal spikes with a frequency of 5.9±2.3Hz, 
amplitude 546±112 µV) in all but one animals (5 out of 6).  
In 2 controls and 2 strong mice 24 hours long EEG monitoring was 
carried out to investigate nocturnal epileptic activity. No animals 
showed exclusively nocturnal seizures, but they exhibited recurrent 
seizures during the whole day. Seizure incidence was the highest in 
the afternoon compared to other periods of the day.  
 
Anatomical changes in the latent phase of epilepsy (1, 3 days 
post pilocarpine) 
Immunostaining against Heat Shock Protein 72 (HSP72) was carried 
out to visualize cells suffering from excitotoxic damage, since the 
presence of this protein confirms the emergence of abnormal 
proteins due to various damaging effects.  
In control hippocampi and in the acute phase of epilepsy 
immunostained cells were never seen, only light background 
staining appeared occasionally in the layers of principal cells. In the 
latent phase positive cells were not seen in weak epileptic animals, 
however, in members of the strong group robust changes occurred 1 
day after the induction of the seizures. Principal cells with Golgi-
like HSP72-staining appeared occasionally in mossy cells of the 
hilus in the str. pyramidale of the CA3, and among the granule cells. 
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Occasionally few immunopositive cells were seen in the CA1 str. 
pyramidale as well.  
Notably, three days after pilocarpine treatment a marked increase in 
HSP72 expression was found in CA1 and CA3 (mostly CA3c) 
pyramidal cells, and in the mossy cells of the hilus.  
Irreversibly damaged cells were visualized with Gallyas silver 
impregnation, during this reaction silver binds to abnormal proteins; 
therefore, irreversibly damaged cells turn black in contrast to other 
living cells with red/orange staining. 
One day or three days after the injection no visual changes could be 
seen in weak animals. In the strong animals 1 day post pilo a dark 
silver deposit was present in hilar neurons undergoing argyrophilic 
degeneration and occasionally in stratum oriens of the CA1 or CA3  
pyramidal cells.  
Three days after pilocarpine administration silver accumulation 
appeared in additional subregions; besides stratum oriens, numerous 
degenerated cells or dendrites were present in strata pyramidale and 
radiatum of the CA1 and CA3 moreover, several degenerating 
somata and dendrites appeared in the hilus. 
 
Analysis of CB1-R distribution in different phases of 
pilocarpine-induced epilepsy 
 
Distribution of CB1-Rs in control tissue 
In control samples intense CB1-R immunostaining was found 
throughout the hippocampus. Immunopositive cell bodies of 
interneurons were seen in all hippocampal subfields, mostly in strata 
radiatum and lacunosum-moleculare of CA1 and CA3, as well as at 
the border of the hilus and in the inner molecular layer of the dentate 
gyrus. Intense staining of CB1-R-positive fibers was observed in 
stratum pyramidale of the cornu Ammonis and in the molecular 
layer of the dentate gyrus (DG). In contrast, less dense labeling was 
observed in the strata lucidum and granulosum. 
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Distribution of CB1-Rs in the acute phase of epilepsy  
In the acute phase (i.e. two hours after seizure onset), epileptic 
hippocampi from members of the weak group showed control-like 
phenotype, namely no major changes were seen in the distribution 
and density of immunolabelled elements. In contrast, the tissue from 
the strong group exhibited a robust decrease in immunopositivity 
throughout the hippocampus, i.e. the dense axonal meshwork found 
in the strata moleculare, radiatum and oriens was substantially 
reduced. Moreover, CB1-R immunopositive boutons forming 
baskets in the principal cell layers could hardly be seen at light 
microscopic level. In this phase a global downregulation of the 
protein appeared. 
 
Reversible changes in CB1-R expression in acute slices (2 hours 
post pilo) 
To investigate the electrophysiological correlates of our anatomical 
findings observed in acute phase, we planned to record the effects of 
CB1–R activation on hippocampal function. In vitro slices were 
prepared from the hippocampi of control and strongly epileptic 
animals. As a first step, immunostaining for CB1-Rs was carried out 
on the slices at two time points: immediately fixed after the slice cut 
and after 2 hours of incubation in an interface-type holding chamber. 
Surprisingly, we observed that after 2 hours of incubation, slices 
from strongly epileptic animals showed control-like distribution of 
CB1-Rs. However, when slices from the same animals were 
immediately fixed after cutting, a similar decrease in CB1-R 
distribution was found as seen in perfusion fixed animals (compared 
to controls).  
 
Increased mortality after seizures in CB1-R knock-out animals 
We addressed the question how seizure susceptibility changes 
occurred in CB1-R knock-out mice. Therefore, 22 controls were 
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examined, 22 CB1-R knockout mice and their 21 wild type 
littermates were injected with pilocarpine in a different set of 
experiments. CB1-R knock-out animals developed very intense 
seizures (typical for strong epileptic animals) as they were more 
susceptible to epilepsy. Of the 22 animals only 3 animals had mild 
seizures , whereas, the 19 animals showing strong seizures died in 
15 minutes.                                                                                                                             
Mice experiencing only mild or no seizures (members of the weak 
group), survived and later were sacrificed in the chronic phase. 
These animals showed no signs of anatomical alterations, NeuN and 
Gallyas labeling was similar to the staining in weak wild type 
littermates. These results demonstrate a protective role of CB1-R 
activation in epilepsy as it has been shown previously. 
 
Ultrastructural changes of CB1-R expression in the acute phase of 
epilepsy 
At the electron microscopic level degenerating profiles were 
observed occasionally throughout the hippocampus.  They were 
mostly oedemic dendritic profiles, axon terminals and spines; 
however, they were not selectively CB1-R-positive. To quantify the 
changes, systematic random sampling was carried out. We could not 
take advantage of dissector method, since one cannot obtain accurate 
counts in a reasonable time, when structures of interest form a very 
small fraction. Moreover, we wished to minimize alterations caused 
by the sprouting of non-positive fibers in the examined area, 
therefore, we have examined a large area (>40.000 µm2) in a single 
plane.  
 A total of 298 terminals were digitized (169 of control tissue, 129 of 
strong epileptic tissue) and analyzed. First, we compared the ratio of 
immunolabelled axon terminals establishing symmetric versus 
asymmetric synapses in the same sample of 298 terminals. The 
percentages of CB1–R immunopositive axon endings forming 
symmetric and asymmetric synapses found in acute epileptic 
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samples were calculated and compared to the percentage observed in 
controls. The analysis revealed no significant change in these ratios 
(control: 79.6 ± 7.6 % in case of asymmetric and 20.4 ± 7.6 % in 
case of symmetric synapses; strong epileptic: 80 ± 4 % in case of 
asymmetric and 20 ± 4 % in case of symmetric synapses, p>0.05; 
Mann-Whitney Utest). To uncover changes in the overall number of 
stained terminals, we counted every stained terminal in a given area 
of str. moleculare, and normalized the results to unit area (40 000 
µm2). Compared to control tissue, a significant decrease was found 
in the number of labeled asymmetric and symmetric synapses 
(control asymmetric: 18.9 ± 2.3; symmetric: 6 ± 0.2; strong epileptic 
asymmetric: 11.8 ± 3.7, symmetric: 3.2 ± 0.7; p<0.05; Mann-
Whitney test).  
In the next step we counted the number of gold particles in the 
membrane of CB1-R-stained terminals and normalized it to the 
perimeter of the terminal membrane (particle /1 µm) to uncover any 
changes occurring on a smaller scale. No difference was found in the 
normalized quantity of gold particles either in case of symmetric 
(control: 0.69±0.29, strong epileptic: 0.59±0.34) or in case of 
asymmetric synapses (control: 0.64±0.27, strong epileptic: 0.63± 
0.33). However, when measuring the perimeter of immunopositive 
terminals an increase occurred in case of symmetric synapses 
indicating enlargement of these terminals. Compared to controls a 
significant increase in perimeter (p<0.05; Mann-Whitney U test) 
was found in case of terminals forming symmetric synapses 
(control: 2±0.67 µm, strong epileptic: 2.63±0.87 µm) however, no 
such difference was observed among stained terminals forming 
asymmetric synapses (control: 1.9±0.76 µm, strong epileptic: 
2.12±0.9 µm). Taken together, the results imply that mechanism(s) 
other than axon terminal degeneration could account for the loss of 
CB1-R staining in the acute phase of epilepsy. 
To understand further changes in CB1-R expression we examined 
other phases as well. 
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Distribution of CB1-Rs in the latent phase of epilepsy (1 and 3 
days post pilo) 
One day after pilocarpine injection CB1-R levels were control-like 
both in weak and strong animals. Three days after pilocarpine 
injection upregulation of CB1-R immunoreactivity occurred in some 
animals of the strong group. There was a gradual recovery in CB1-R 
intensity 1 and 3 days post pilo. 3 days after status epilepticus 
principal cells began to degenerate and HSP72 staining was more 
extended referring to excitotoxic damage caused by the initial 
seizures. However, in the latent phase the decreased intensity of the 
receptor staining was no longer observed. CB1-R staining proved to 
be control-like or moderately increased. 
 
Distribution of CB1-Rs in the chronic phase of epilepsy (1 and 2 
months) 
To study the long-term changes in CB1-R levels, their distribution 
was examined one month after pilocarpine injection, in the chronic 
phase. In general, similar alterations in CB1-R staining were found 
in these animals as we observed earlier with antibody recognizing 
only CB1-R at inhibitory terminals (Magloczky et al., 2010). In 
epileptic animals of the weak group the distribution of CB1-Rs was 
mostly control-like. Occasionally, a highly restricted upregulation 
appeared in str. pyramidale of CA1. In the sclerotic samples the 
general CB1-R immunostaining was enhanced throughout the 
hippocampus. The density of immunostained fibers in CA1 
increased heavily in surviving elements of strata pyramidale and 
radiatum. Similarly, in DG a dense CB1-R-positive axonal plexus 
was found in strata moleculare and granulosum. Immunopositive 
interneuron somata were present both in the dentate gyrus and in the 
CA1 and CA3 areas.  
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Ultrastructural analysis of CB1-R distribution in the chronic 
phase 
At the electron microscopic level, numerous glial elements and 
occasionally degenerating profiles were seen, changes that are 
typical for epileptic tissues, however glial elements were not 
positive for CB1-R staining. The general ultrastructural features of 
CB1-R-positive elements were unchanged; nevertheless, the number 
of stained terminals increased significantly (p<0.05). Changes in the 
ratio of stained terminals establishing symmetric versus asymmetric 
synapses were analyzed (169 controls, 178 strong epileptic). In 
epileptic animals the ratio was significantly changed; the mean 
percentage in control tissue was 79.6 ± 7.64% in case of asymmetric 
and 20.4 ± 7.6% in case of symmetric synapses, in strong epileptic 
tissue 51.4 ± 3.9% of the examined terminals proved to be 
asymmetric, whereas 48.6 ± 3.9% was symmetric (p<0.05; Mann-
Whitney test). These results may suggest either a loss of stained 
asymmetric synapses or an increase of symmetric synapses, or both.  
To address this question, we used systematic random sampling as 
described above and digitized every stained terminal in a given area 
of str. moleculare, and normalized the results to unit area (40.000 
µm2). Compared to control tissue a significant increase was found in 
the number of CB1-R-positive asymmetric and symmetric synapses 
(control asymmetric: 18.9 ± 2.3 symmetric: 6 ± 0.2; epileptic: 
asymmetric: 34.9 ± 10.9, symmetric: 32.3 ± 18.5, p<0.05; Mann-
Whitney test). During the analysis of immunogold-labeled axon 
terminals, in certain terminals we noticed an increase in the number 
of immunogold particles in the hippocampi of chronically epileptic 
animals of the strong group. 
 To quantify these changes, immunogold particles were counted in 
302 (125 controls and 177 strong epileptic) terminals. The number 
of gold particles attached to the membrane of CB1-R stained axon 
terminals forming symmetric or asymmetric synapses was counted 
and normalized to unit perimeter of the axon terminal membrane 
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(particle/1 µm). No difference was found between asymmetric 
synapses in control and epileptic tissue in the average quantity of 
gold particles (control: 0.64 ± 0.27, strong epileptic: 0.633 ± 0.46, 
p>0.05, Mann-Whitney test).  In contrast, the number of 
immunogold particles significantly increased in axon terminals 
forming symmetric synapses (control: 0.69 ± 0.29, strong epileptic: 
0.99 ± 0.49, p<0.05, Mann-Whitney test). Furthermore, the 
perimeter of immunopositive terminals establishing symmetric 
synapses significantly increased in strong epileptic animals in the 
chronic phase (control: 1.99±0.67 µm, strong epileptic: 2.7±0.9 µm). 
No such change was observed in terminals establishing asymmetric 
synapses (control: 1.89±0.8 µm, strong epileptic: 2.22±0.93 µm). 
 
In summary, we found that the ratio of stained symmetric versus 
asymmetric synapses was unchanged in the acute phase, whereas a 
significant difference appeared in the chronic phase. The number of 
immunolabelled axon terminals forming asymmetric and symmetric 
synapses was decreased in the acute and increased in the chronic 
phase. In addition, the number of gold particles indicating the 
presence of CB1-Rs was increased on terminals forming symmetric 
synapses but only in the chronic phase (no such difference occurred 
in case of asymmetric synapses). These results may indicate a 
transient decrease of the receptor function in the acute phase leading 
to abnormally high transmitter release. In contrast, the elevation of 
CB1-R function in the chronic phase, may secure the balance of 
transmitter release, acting as an extremely powerful circuit-breaker 
on GABAergic and glutamatergic transmission. 
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Conclusions 
 
In our model various aspects of epileptic cell loss and reorganization 
are similar to that seen in human TLE. In human TLE patients 
sclerosis is the most common cell loss pattern; therefore, alterations 
in animals with similar cell loss are likely to be relevant to human 
TLE. 
 On the basis of our results the strength of seizures in the acute phase 
can be used to predict future changes (e.g. cell loss) in the chronic 
phase. since the vulnerability of cells differs between “weak” and 
“strong” groups, as indicated by HSP72-expression in the latent 
phase. In case of CB1-R-staining, robust changes can only be found 
in animals with strong acute seizures. In animals with milder 
seizures and hardly any cell loss, changes in CB1-R distribution 
remains undetectable. In “strong” mice the expression of CB1-Rs 
related to the GABAergic and glutamatergic axon terminals is 
strongly decreased without specific degeneration in the acute phase. 
In addition, a significant increase can be seen in the number of CB1-
Rs in a single terminal, but only in terminals forming symmetric 
synapses. The death of CB1-R knock-ou mice with strong acute 
seizures suggest that CB1-Rs may have a key role in the control of 
the first seizures, and thereby may prevent the seizures from 
reaching the “no-return” state. Thus, the decrease of CB1-Rs in 
animals with strong acute seizures may lead to elevation of 
glutamate release during acute seizures, as well as to the subsequent 
development of recurrent seizures, reorganization and cell loss. The 
increased density of CB1-Rs in the chronic phase may serve as a 
protective mechanism in most cases as proposed in earlier studies, 
and confirmed in the present study as well. The unchanged target 
distribution of CB1-R-positive elements indicate that the increased 
endocannabinoid tone is necessary on all cellular domains,  thus; the 
greater input affects the somatic and dendritic regions as well. 
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